Back to Top Skip to main content Skip to sub-navigation

BAMC expands use of ECMO to treat severe COVID-19 patients

Medical personnel wearing masks, looking at paperwork on desk Army Maj. Michal Sobieszczyk, staff physician, Interventional Pulmonology and Critical Care Medicine, reviews paperwork in a COVID-19 intensive care unit at Brooke Army Medical Center, Joint Base San Antonio-Fort Sam Houston, Texas. (Photo by James Camillocci.)

Recommended Content:

Coronavirus

Extracorporeal membrane oxygenation, or ECMO, is a heart-lung bypass intervention that is proving to be lifesaving for some patients with COVID-19.

The staff at Brooke Army Medical Center at Joint Base San Antonio Fort Sam Houston in Texas has expanded the use of this highly specialized treatment in a “last line of defense” for critically ill COVID-19 patients. 

 “ECMO is often the last line of defense for the most critically ill patients with severe pulmonary disease,” said Air Force Col. (Dr.) Patrick Osborn, BAMC’s deputy commander for Surgical Services. “Whether due to COVID-19 or another condition, ECMO provides a life-support option that can potentially save lives when all other options are exhausted.”

BAMC, one of the few local facilities that offer the treatment, is currently providing up to one-third of the ECMO capability for the San Antonio area’s most severely ill community members, veterans and military beneficiaries suffering from the virus.

“As much as able, BAMC is easing the burden on local healthcare resources by admitting civilian ECMO patients,” Osborn said.

ECMO Explained

This treatment, which requires a multidisciplinary team of specially trained medical personnel, is used in the intensive care unit when a patient experiences heart and/or lung failure. The ECMO machine removes blood from central vessels in a patient’s body, circulates it through an artificial lung, oxygenates it, and delivers the blood back into the bloodstream. In essence, it replaces the natural functions of the heart and lungs while treatments and natural healing of the affected organs take place. 

“ECMO is not a treatment for any specific disease. It works by keeping critically ill patients alive and buying time for us to address their underlying condition,” explained Air Force Col. (Dr.) Phillip Mason, medical director for BAMC’s Adult ECMO program. “In some cases, we can reduce a patient's chance of dying from 80 to 90 % down to 30 to 40 %. While 30 to 40 % is still high, it represents a significant improvement and translates into many lives saved.”

Established in October 2012, BAMC has the only adult ECMO center in the Department of Defense and remains one of the few centers with global air transportable ECMO capability. The multi-service ECMO team has traveled around the global to pick up service members in need of the treatment.

While taking care of military beneficiaries is BAMC’s primary mission, the organization is able to support civilian ECMO patients through a special Department of Defense program. The experience gained ensures the ECMO team sustains the skills required to mobilize worldwide to treat and transport patients back to BAMC, Osborn said.

COVID-19 Care

Pre-COVID, BAMC averaged four ECMO patients at a a time due to the highly specialized personnel, training and equipment required to care for patients. In recent weeks, the hospital has expanded its capability and is treating up to nine patients at once, most whom are battling COVID-19. 

An ECMO team carefully considers the treatment after other lifesaving measures, such as oxygen therapy or a ventilator, have been exhausted.

“The vast majority of the critical care community believes that ECMO is effective as a rescue therapy for respiratory failure that does not respond to conventional therapies,” Mason noted. 

BAMC is part of a multinational observational trial of ECMO’s use for COVID-19 that should help to reveal evidence-based proof of the treatment’s effectiveness, Mason said. 

“While COVID is a complex disease effecting many organ systems, its primary manifestation is respiratory failure so there is at least some reason to believe ECMO will be effective,” he said, noting the treatment is often used for other viral respiratory illnesses, such as influenza.

With the program in place for nearly a decade, BAMC’s COVID team is accustomed to working closely with local hospitals in the event a patient may be a candidate for ECMO. This collaboration has stepped up in recent months, creating a larger influx of patients. 

To expand capacity to meet the growing community need, BAMC called on its ECMO team to train additional nurses and technicians on the equipment, while also leaning on personnel from the U.S. Army Institute of Surgical Research (ISR) Burn Center, which is housed in the hospital, to assist. 

“With the support of the ISR we have been able to expand our ECMO capacity significantly,” said Army Maj. (Dr.) Michal Sobieszczyk, Staff Physician, Interventional Pulmonology and Critical Care Medicine. "The BAMC and ISR bedside nurses have been instrumental in making the ECMO mission a success" 

Lifesaving Treatment

ECMO may be a last resort for COVID patients, but one that has proved lifesaving for many.

Sobieszczyk recalled one recent patient in his late 20s who was placed on ECMO two times, once for COVID-19 pneumonia, from which he recovered, and the second time for a bacterial pneumonia and sepsis. 

“He required a high level of support and came close to dying several times,” Sobieszczyk said. He was able to be weaned off ECMO and was decannulated (had tubes removed).

As a last-resort measure, ECMO is a high-stakes endeavor, Mason noted. “We have the highest highs and the lowest lows. But each life saved is incredibly rewarding for us, and a testament to the importance of this treatment.”

 “The ECMO team is honored to support the community during this pandemic,” he said. “Not only are we able to help the civilian population, but at the same time use this as an opportunity to enhance our mission readiness. It gives everyone a sense of purpose and mission, something we all strive for in the military.”

You also may be interested in...

DHA-PI 6205.01: Medical Logistics Guidance for the DoD Coronavirus Disease 2019 (COVID-19) Vaccination Program

Policy

This Defense Health Agency-Procedural Instruction (DHA-PI), based on the authority of References (a) and (b), and in accordance with the guidance of References (c) through (n), establishes the Defense Health Agency's (DHA's) procedures for ordering, receiving, and managing COVID-19 Vaccines inventory and ancillary kits.

DHA-IPM 20-004: Department of Defense (DoD) Coronavirus Disease 2019 (COVID-19) Vaccination Program Implementation

Policy

This Defense Health Agency (DHA) Interim Procedures Memorandum (IPM), based on the authority of References (a) through (d), and in accordance with the guidance cited in References (e) through (aa), establishes the DHA’s procedures to implement instructions, assign responsibilities, and prescribe procedures for the COVID-19 Vaccination Program. This DHA-IPM applies to DHA, DHA Components (activities under the authority direction, and control of the DHA), Military Departments (MILDEP), and the United States Coast Guard (CG). This DHA-IPM cancels and replaces DHA-IPM 20-004, “Department of Defense (DoD) Coronavirus Disease 2019 (COVID-19) Vaccination Program Implementation,” December 13, 2020.

TAB A MEO COVID19 Medical Coding Policy

Policy

Memorandum for DHA Staff - Military Medical Treatment Facilities to Implement Updated DHA COVID-19 Medical Coding Policy

  • Identification #: N/A
  • Date: 3/25/2021
  • Type: Memorandums
  • Topics: Coronavirus

DHA COVID19 Medical Coding PolicyV5 1v

Policy

Establishes the DHA procedures to standardize the coding for Coronavirus 2019 (COVID-19) within military medical treatment facilities (MTFs). This memorandum replaces DHA-Policy Memorandum 20-003 of July 1, 2020. Attachment 1 was updated to include the 2021 procedure and diagnosis codes for COVID-19, including the new vaccination and treatment codes.

  • Identification #: 20-003
  • Date: 3/25/2021
  • Type: Memorandums
  • Topics: Coronavirus

Supplemental Guidance for Providing DoD Coronavirus Disease 2019 Vaccines to DoD Contractor Employees and Select Foreign Nationals

Policy

This memorandum provides supplemental guidance on the provision of coronavirus disease 2019 (COVID-19) vaccines, in accordance with reference (a). The Defense Health Agency (DHA) is the lead coordinating DoD Component for executing this guidance, in coordination with the Military Departments and other DoD Components as appropriate.

HA Guidance for Coronavirus Disease 2019 (COVID-19) Laboratory Pre-Testing Questionnaire

Policy

This memorandum provides guidance for a COVID-19 laboratory pre-testing questionnaire that will be mandatory for all Active Duty Service members and encouraged for all other DoD beneficiaries treated at military medical treatment facilities.

Executive Order on Ensuring Access to United States Government COVID-19 Vaccines

Policy

This EO outlines who should receive priority access to COVID-19 vaccines developed in the United States or procured by the United States Government (“United States Government COVID-19 Vaccines”).

Coronavirus Disease 2019 Vaccine Guidance

Policy

This memorandum provides guidance on the provision of coronavirus disease 2019 (COVID-19) vaccines. The Defense Health Agency (DHA) is the lead coordinating DoD Component for executing this guidance, in coordination with the Military Departments and other DoD Components.

DHA-AI 3020-01: Return to the Workplace Staffing Plan in the Coronavirus Disease 2019 Environment

Policy

This Defense Health Agency-Administrative Instruction (DHA-AI), based on the authority of References (a) through (b) and in accordance with the guidance of References (c) through (z3), establishes the Defense Health Agency's (DHA) plan to return to full operations and support the whole-of-government response, during the Coronavirus Disease 2019 (COVID-19) pandemic. This DHA-AI also provides a preventive plan to monitor and assess for the appearance of new cases and implement those processes that will prevent them from impacting the workforce. The processes describe herein are intended to offer an actionable plan for the workforce to re-enter DHA Administrative Offices. See Appendix 1 for a summary of the DHA Administrative Office Reopening Plan. The plan uses the Force Health Protection Guidance and Health Protection Conditions (HPCON), in accordance with Reference (d), to ensure protection for the workforce, including the most vulnerable-to-serious complications from the virus while enabling DHA Administrative Offices to continue its mission. See Appendix 2 for the conceptual HPCON framework.

  • Identification #: 3020-01
  • Date: 11/3/2020
  • Type: Administrative Instructions
  • Topics: Coronavirus

DHA AI 3020.01: Return to the Workplace Staffing Plan in the Coronavirus Disease 2019 (COVID-19) Environment

Policy

This Defense Health Agency-Administrative Instruction (DHA-AI), establishes the Defense Health Agency’s (DHA) plan to return to full operations and support the whole-of-government response, during the Coronavirus Disease 2019 (COVID-19) pandemic and in preparation for regression or resurgence in COVID-19 cases that could impact the workforce.

  • Identification #: DHA AI 3020.01
  • Date: 6/12/2020
  • Type: Administrative Instructions
  • Topics: Coronavirus
Showing results 1 - 10 Page 1 of 1

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.